Javid Moslehi, MD
Cardiovascular Disease · San Francisco, CANPI 1538123716
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $287,648 of the $306,533 with a category attached, or 93.8%. 28 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 27.9% of the total. Reporting peaked in 2020 at $95,818 and has fallen 71.4% since, to $27,443 in 2025. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 149 payments — averaging $2057.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$86K
- AstraZeneca$40K
- Pfizer$34K
- Takeda Pharmaceuticals U.S.A., Inc.$30K
- Astrazeneca UK Limited$29K
- Daiichi Sankyo Inc.$21K
- plus $66K from 22 others
Across 19 payments — averaging $19,283 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$307K
- Pfizer$29K
- Takeda Pharmaceuticals U.S.A., Inc.$21K
- Incyte Corporation$9K
What the payments were for
- Consulting fees$287,64894%
- Speaking & faculty fees$6,1502%
- Travel & lodging$11,3504%
- Food & beverage$1,3850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 44 | $85,613 |
| AstraZeneca | 16 | $39,903 |
| Pfizer | 3 | $34,460 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $29,990 |
| Astrazeneca UK Limited | 18 | $29,227 |
| Daiichi Sankyo Inc. | 12 | $20,925 |
| Sumitomo Pharma America, Inc. | 4 | $9,915 |
| Deciphera Pharmaceuticals Inc. | 5 | $8,800 |
| Bayer | 1 | $7,700 |
| Beigene USA, Inc. | 1 | $4,550 |
| Regeneron | 5 | $4,200 |
| Teva Pharmaceuticals USA, Inc. | 1 | $3,400 |
| Myovant Sciences Inc. | 1 | $3,320 |
| Immunocore Limited | 2 | $3,301 |
| Novartis | 2 | $3,000 |
| Sobi, Inc | 1 | $2,870 |
| Janssen Scientific Affairs, LLC | 1 | $2,790 |
| Mallinckrodt Hospital Products Inc. | 1 | $2,640 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $2,100 |
| Boehringer Ingelheim | 1 | $1,740 |
| F. Hoffmann-la Roche AG | 1 | $1,470 |
| Amgen | 1 | $1,190 |
| Johnson & Johnson | 1 | $1,170 |
| Incyte Corporation | 3 | $1,000 |
| GSK | 5 | $660 |
| Sanofi | 4 | $398 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $118 |
| Medtronic | 1 | $84 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$306,533 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Colchicine | 13 | $4,937 |
| Metoprolol Succinate | 38 | $478 |
| Amlodipine Besylate | 16 | $114 |
| Atorvastatin Calcium | 11 | $35 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in San Francisco
- Philip SagerSan Francisco$675K
- Tony ChouSan Francisco$301K
- Lloyd KleinSan Francisco$149K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.